The development of chronic infections and cancer is facilitated by a variety of immune
subversion mechanisms, such as the production of anti‐inflammatory cytokines, induction of …

Tumors can evade immune detection by exploiting inhibitory immune checkpoints such as
the programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathway …

Lung cancer has shown a decrease in incidence and mortality in recent decades; however,
it remains one of the cancers with the highest incidence and ranks first in cancerrelated …

Purpose: The success of immune checkpoint inhibitors strengthens the notion that tumor
growth and regression are immune regulated. To determine whether distinct tissue immune …

Although many studies have addressed the prognostic value of programmed cell death-
ligand 1 (PD-L1) expression in lung cancer, the results remain controversial. A systematic …

Recently, immunotherapy has been shown to be an effective and helpful therapeutic option
for the treatment of advanced non-small-cell lung cancer (NSCLC). The activity of antitumor …

Non–small cell lung cancer (NSCLC) is one of the most prevalent cancers and is
responsible for a large proportion of all cancer-related deaths. Current treatment options are …

Background Immune checkpoint inhibitors, which are a milestone in anti-cancer therapy,
have been applied in the treatment of multiple malignancies. Real-world data have …

The emergence of immunotherapy as a first-or second-line of treatment has revolutionized
the therapeutic management of lung cancer patients. However, not all lung cancer patients …

PD-L1 expression testing is mandatory prior to pembrolizumab prescription in non-small cell
lung cancer. Our service offers PD-L1 testing using the PD-L1 IHC 22C3 pharmDx assay, in …